Arrowhead Pharmaceuticals and Madrigal Announce MASH Deal
PASADENA, Calif., United States – May 5, 2026 Arrowhead Pharmaceuticals Inc. has entered into an exclusive global licensing agreement...
AI drug discovery Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
PASADENA, Calif., United States – May 5, 2026 Arrowhead Pharmaceuticals Inc. has entered into an exclusive global licensing agreement...
RESEARCH TRIANGLE PARK, N.C. – May 4, 2026 Opus Genetics Inc. has announced that its investigational gene therapy OPGx-LCA5...
IRVING, Texas – May 4, 2026 Caris Life Sciences has secured MolDX approval for its flagship Caris ChromoSeq™ assay,...
FRIENDSWOOD, TEXAS, May 04, 2026 Castle Biosciences has announced the presentation of new clinical data at Digestive Disease Week...
NEW YORK, NY, May 4, 2026 GRIN Therapeutics, Inc. has announced the initiation of its pivotal Phase 3 Beeline...
Boston, Massachusetts, United States | April 30, 2026 A new study led by researchers at Harvard Medical School and...
Stockholm, Sweden | April 30, 2026 Moleculent has announced the successful closing of a $20 million financing round, aimed...
Ballerup, Denmark | April 30, 2026 LEO Pharma has announced a definitive agreement to acquire Replay, significantly expanding its...
Houston, USA | May 1, 2026 Diakonos Oncology has reported positive Phase 1 clinical data for its investigational DOC1021...
BOSTON, Massachusetts, May 2026 Kernal Biologics announced it will present new data on its mRNA 2.0 platform and T-cell-targeted...
